tiprankstipranks
Advertisement
Advertisement

RNTX Stock Latest News

Buy Rating Reaffirmed on LTI-03 Data and Upcoming RENEW Trial, Price Target Maintained at $8
RatingsBuy Rating Reaffirmed on LTI-03 Data and Upcoming RENEW Trial, Price Target Maintained at $8
1d ago
RNTX
Rein Therapeutics Shareholders Approve Governance and Stock Changes
PremiumCompany Announcements
Rein Therapeutics Shareholders Approve Governance and Stock Changes
16d ago
8K
RNTX
Rein Therapeutics announces RENEW clinical trial open for enrollment
PremiumThe Fly
Rein Therapeutics announces RENEW clinical trial open for enrollment
17d ago
RNTX
Maxim starts Rein Therapeutics at Buy amid de-risked LTI-03 program
PremiumThe Fly
Maxim starts Rein Therapeutics at Buy amid de-risked LTI-03 program
18d ago
RNTX
Rein Therapeutics initiated with a Buy at Maxim
PremiumThe Fly
Rein Therapeutics initiated with a Buy at Maxim
18d ago
RNTX
Rein Therapeutics price target lowered to $8 from $10 at H.C. Wainwright
PremiumThe FlyRein Therapeutics price target lowered to $8 from $10 at H.C. Wainwright
2M ago
RNTX
Rein Therapeutics Prices $50 Million Public Equity Offering
Premium
Company Announcements
Rein Therapeutics Prices $50 Million Public Equity Offering
3M ago
8K
RNTX
Rein Therapeutics provides update on RENEW clinical trial
Premium
The Fly
Rein Therapeutics provides update on RENEW clinical trial
3M ago
RNTX
Rein Therapeutics files to sell 30M shares of common stock
PremiumThe Fly
Rein Therapeutics files to sell 30M shares of common stock
3M ago
RNTX
RNTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
RNTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
RNTX
Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright
PremiumThe Fly
Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright
4M ago
RNTX
Rein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside
PremiumRatings
Rein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside
4M ago
RNTX
Rein Therapeutics doses first patient in Phase 2 trial of LTI-03
PremiumThe FlyRein Therapeutics doses first patient in Phase 2 trial of LTI-03
5M ago
RNTX
Rein Therapeutics Completes Private Placement of Notes
Premium
Company Announcements
Rein Therapeutics Completes Private Placement of Notes
5M ago
8K
RNTX
Rein Therapeutics Announces Immediate Board Director Resignation
Premium
Company Announcements
Rein Therapeutics Announces Immediate Board Director Resignation
6M ago
8K
RNTX
Rein Therapeutics downgraded to Hold from Buy at Brookline
PremiumThe Fly
Rein Therapeutics downgraded to Hold from Buy at Brookline
7M ago
RNTX
Rein Therapeutics receives orphan drug designation from EMA for LTI-03
PremiumThe Fly
Rein Therapeutics receives orphan drug designation from EMA for LTI-03
7M ago
RNTX
Rein Therapeutics Raises Capital via Private Note Offering
PremiumCompany Announcements
Rein Therapeutics Raises Capital via Private Note Offering
7M ago
8K
RNTX
Rein Therapeutics Ends Key Financial Agreements
PremiumCompany Announcements
Rein Therapeutics Ends Key Financial Agreements
8M ago
8K
RNTX
Rein Therapeutics: Buy Rating Driven by Innovative IPF Treatment and Strong Growth Potential
PremiumRatingsRein Therapeutics: Buy Rating Driven by Innovative IPF Treatment and Strong Growth Potential
9M ago
RNTX
Rein Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Rein Therapeutics Reports Q3 2025 Financial Results
9M ago
RNTX
Rein Therapeutics’s LTI-03 Gains Momentum with FDA Clearance and Promising Trial Developments
Premium
Ratings
Rein Therapeutics’s LTI-03 Gains Momentum with FDA Clearance and Promising Trial Developments
9M ago
RNTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >